{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Control&page=48",
    "query": {
      "intervention": "Safety Control",
      "page": 48
    },
    "page_size": 10
  },
  "pagination": {
    "page": 48,
    "page_size": 10,
    "total_count": 14130,
    "total_pages": 1413,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Control&page=49&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Control&page=47&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-05T04:33:17.055Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06980948",
      "title": "Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Neuropathic Pain"
      ],
      "interventions": [
        {
          "name": "ST-503",
          "type": "GENETIC"
        },
        {
          "name": "Sham (No Treatment)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "PROCEDURE"
      ],
      "sponsor": "Sangamo Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2025-12-04",
      "completion_date": "2028-07",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-05T04:33:17.055Z",
      "location_count": 11,
      "location_summary": "Scottsdale, Arizona • Little Rock, Arkansas • La Jolla, California + 8 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06980948"
    },
    {
      "nct_id": "NCT01056315",
      "title": "A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Painful Diabetic Neuropathy"
      ],
      "interventions": [
        {
          "name": "GRT3938Y",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Grünenthal GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 553,
      "start_date": "2009-11",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2019-10-28",
      "last_synced_at": "2026-11-05T04:33:17.055Z",
      "location_count": 61,
      "location_summary": "Fairhope, Alabama • Homewood, Alabama • Tucson, Arizona + 36 more",
      "locations": [
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01056315"
    },
    {
      "nct_id": "NCT06465108",
      "title": "Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypoparathyroidism"
      ],
      "interventions": [
        {
          "name": "MBX 2109",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "MBX Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 64,
      "start_date": "2024-08-08",
      "completion_date": "2025-06-04",
      "has_results": false,
      "last_update_posted_date": "2026-03-20",
      "last_synced_at": "2026-11-05T04:33:17.055Z",
      "location_count": 27,
      "location_summary": "Sacramento, California • Jacksonville, Florida • Miami, Florida + 22 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Macon",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06465108"
    },
    {
      "nct_id": "NCT00995787",
      "title": "Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type II Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "AZD1656",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "30 Years to 75 Years"
      },
      "enrollment_count": 75,
      "start_date": "2009-10",
      "completion_date": "2010-02",
      "has_results": false,
      "last_update_posted_date": "2010-02-26",
      "last_synced_at": "2026-11-05T04:33:17.055Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00995787"
    },
    {
      "nct_id": "NCT00690716",
      "title": "The Effect of Nasal Carbon Dioxide (CO2) in the Treatment of Mild Headache in People Who Experience Migraines",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Nasal CO2",
          "type": "DRUG"
        },
        {
          "name": "Inactive Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Capnia, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 292,
      "start_date": "2008-08",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2012-08-15",
      "last_synced_at": "2026-11-05T04:33:17.055Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Stanford, California • East Hartford, Connecticut + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "East Hartford",
          "state": "Connecticut"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00690716"
    },
    {
      "nct_id": "NCT02808104",
      "title": "Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Attention Deficit Disorder With Hyperactivity"
      ],
      "interventions": [
        {
          "name": "mazindol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NLS Pharmaceutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 84,
      "start_date": "2016-08",
      "completion_date": "2017-03-28",
      "has_results": false,
      "last_update_posted_date": "2017-04-06",
      "last_synced_at": "2026-11-05T04:33:17.055Z",
      "location_count": 7,
      "location_summary": "Newport Beach, California • Jacksonville, Florida • Marshfield, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Marshfield",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester Hills",
          "state": "Michigan"
        },
        {
          "city": "Saint Charles",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02808104"
    },
    {
      "nct_id": "NCT07770685",
      "title": "A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "ASP2767",
          "type": "DRUG"
        },
        {
          "name": "Sham ASP2767",
          "type": "DRUG"
        },
        {
          "name": "Prophylactic Regimen A",
          "type": "DRUG"
        },
        {
          "name": "Prophylactic Regimen B",
          "type": "DRUG"
        },
        {
          "name": "Placebo for prophylactic regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 156,
      "start_date": "2026-10-07",
      "completion_date": "2030-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-22",
      "last_synced_at": "2026-11-05T04:33:17.055Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07770685"
    },
    {
      "nct_id": "NCT04170543",
      "title": "A Phase 2b Diabetic Kidney Disease Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "MEDI3506",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "101 Years",
        "sex": "ALL",
        "summary": "18 Years to 101 Years"
      },
      "enrollment_count": 609,
      "start_date": "2019-11-18",
      "completion_date": "2023-05-16",
      "has_results": true,
      "last_update_posted_date": "2024-07-10",
      "last_synced_at": "2026-11-05T04:33:17.055Z",
      "location_count": 49,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 42 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04170543"
    },
    {
      "nct_id": "NCT05158335",
      "title": "Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "MBX 2109 (Part A)",
          "type": "DRUG"
        },
        {
          "name": "MBX 2109 (Part B)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MBX Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "21 Years to 60 Years"
      },
      "enrollment_count": 76,
      "start_date": "2021-11-10",
      "completion_date": "2023-06-20",
      "has_results": false,
      "last_update_posted_date": "2023-08-09",
      "last_synced_at": "2026-11-05T04:33:17.055Z",
      "location_count": 2,
      "location_summary": "Dallas, Texas • Madison, Wisconsin",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05158335"
    },
    {
      "nct_id": "NCT00677365",
      "title": "Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis (CF)"
      ],
      "interventions": [
        {
          "name": "MP-376",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 151,
      "start_date": "2008-06",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2024-12-27",
      "last_synced_at": "2026-11-05T04:33:17.055Z",
      "location_count": 39,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00677365"
    }
  ]
}